Investigating antibodies that target oxidized phospholipids to improve bone health in older adults
Official title: Antibodies against Oxidized Phospholipids and Osteoporosis
Funded at Central Arkansas Veterans Hlthcare Sys · NIH-11009539 · Data updated 2026-11-12
This study is looking at how a special antibody might help prevent bone loss as we age, which could be really helpful for older adults dealing with osteoporosis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Central Arkansas Veterans Hlthcare Sys NIH-funded |
| Lab location | 1 site (North Little Rock, United States) |
| Project start | October 1, 2019 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01BX003901-06 |
| Project ID | NIH-11009539 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults at risk for osteoporosis or those experiencing age-related bone loss.
✕Less likely to help
Patients who are younger and do not have any risk factors for osteoporosis may not benefit from this research.
What this research studies
This research focuses on understanding how antibodies against oxidized phospholipids (OxPLs) can help prevent bone loss associated with aging and osteoporosis. The study uses transgenic mice that produce a specific antibody, E06-scFv, which has shown promise in increasing bone mass and promoting bone formation. By analyzing the effects of these antibodies on bone cells and their genetic activity, the research aims to uncover new therapeutic strategies for enhancing bone health in older individuals.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or reverse bone loss in older adults, reducing the risk of osteoporosis-related fractures.
How similar studies have gone: Previous research has shown that targeting oxidized phospholipids can have beneficial effects in other conditions, suggesting potential success for this novel approach in osteoporosis.
Where this research is happening
-
Central Arkansas Veterans Hlthcare Sys
North Little Rock, United States Active
Researchers
- Principal investigator: Ambrogini, Elena — Central Arkansas Veterans Hlthcare Sys
- Study coordinator: Ambrogini, Elena
Related research
Other NIH-funded projects on the same topics.
-
Or olive-oil derived compound to prevent bone loss in women
A safe, orally taken nutraceutical may help prevent osteoporosis in adult women by supporting bone formation and reducing bone loss.
-
When to stop, switch, or pause long-term osteoporosis medicines for older adults
This project looks at whether stopping, switching, or taking breaks from long-term osteoporosis drugs changes fracture risk and side effects for older adults.
-
Cortical Bone Mechanics Technology to better screen for osteoporosis
A new noninvasive test called CBMT uses ulnar flexural rigidity to predict fracture risk better than standard bone density tests, helping adults who may be at risk for osteoporosis.
-
Gene therapy for osteoporosis linked to ALDH2 deficiency in postmenopausal East Asian women
A gene therapy approach is being developed to reduce osteoporosis risk in postmenopausal East Asian women who have ALDH2 deficiency and drink alcohol.
-
Metabolomics clues to osteoporosis risk in diverse populations
A study using small molecules in blood samples to understand osteoporosis risk, with a focus on aging, ethnicity, and sex differences.
-
Single-Cell Study of Bone Cells to Understand Osteoporosis
Researchers will study individual bone-related cells from people to uncover why aging leads to weaker bones and higher fracture risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.